- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Cuban HB vaccine undergoes clinical trials in 8 countries
English.news.cn 2015-10-23 17:23:42 [More]
HAVANA, Oct. 23 (Xinhua) -- A new Cuban vaccine for hepatitis B is undergoing clinical trials in seven Asian countries apart from Cuba, the Contemporanea newspaper reported Thursday.
The seven countries are Australia, New Zealand, South Korea, Singapore, China, the Philippines and Thailand, said Iris Lugo, a specialist from the Center for Genetic Engineering and Biotechnology (CIGB), which developed the vaccine.
The vaccine, HeberNasvac, prevents the progression of the disease or keeps it under control for a longer time, causes fewer adverse reactions, according to the CIGB. The treatment period is shorter, not exceeding 20 weeks.
Moreover, clinical trials have shown that the vaccine has greater antiviral efficacy than other applied conventional drugs.
Within a few months, Lugo said, the drug is expected to obtain the sanitary registration granted by the Center for State Control of Drugs and Medical Devices, allowing it to be used in Cuba in 2016.
The scientist added that some foreign companies have shown interest in its marketing, including French company Abivax, which has involved with the development of the new vaccine.
According to the World Health Organization, about 1 million people die each year from diseases related to the hepatitis B virus, which also continues to be the main risk factor for liver cancer and other serious complications, including esophageal varices.
Editor: Tian Shaohui
古巴乙肝疫苗经过临床试验在8个国家
English.news.cn 2015年10月23日17点23分42秒[详细]
哈瓦那10月23日电(记者) - 一个新的古巴疫苗,B型肝炎是由古巴正在进行临床试验在七个亚洲国家开的当代美术馆报纸周四报道。
这七个国家是澳大利亚,新西兰,韩国,新加坡,中国,菲律宾和泰国,在虹膜卢戈,来自中心的遗传工程和生物技术(CIGB),它开发疫苗的专家。
的疫苗,HeberNasvac,防止疾病的进展或对其进行控制,对于较长的时间,导致更少的不良反应,根据CIGB。治疗时间短,不超过20周。
此外,临床试验表明,该疫苗具有更大的抗病毒效力比其他应用常规药物。
在短短几个月内,卢戈说,该药物有望获得授予的中心药品的状态控制和医疗器械的卫生注册,允许它被用于古巴在2016年。
这位科学家补充说,一些外国公司已经显示在其营销的兴趣,其中包括法国公司Abivax,已参与了新疫苗的开发。
据世界卫生组织,约1万人每年死于与乙肝病毒,这也仍然是肝癌等严重的并发症,包括食管静脉曲张的主要危险因素疾病。
编辑:田稍隳 |
|